FP010 / FAPON - LARVOL DELTA

Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025 (PRNewswire) - "Fapon Biopharma...is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships...The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities."

P1 data • Preclinical • Immunology • Solid Tumor

A novel anti-EGFR × IL-10M (FP010) fusion protein for solid tumor therapy (AACR 2025) - "In contrast, Panitumumab × wt IL-10 caused a remarkable decrease of erythrocytes at the same dose, consistent with the adverse effects of PEGylated IL-10 observed in clinical trials.FP010 has demonstrated significant antitumor activity in vitro and in vivo, with acceptable adverse effects observed in cynomolgus monkeys. These data indicate that FP010 has great potential for cancer immunotherapy, especially for tumors with resistance to PD-1/PD-L1 inhibitors due to T cell exhaustion."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • IFNG • IL10 • STAT3